• Explore /
  • Poster
  • / PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an <em>FGFR2</em> gene fusion/rearrangement.

PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement.

Abstract Poster

Authors

Ghassan Abou-Alfa

Ghassan K. Abou-Alfa

Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY

Ghassan K. Abou-Alfa , Ivan Borbath , Lipika Goyal , Angela Lamarca , Teresa Macarulla , Do-Youn Oh , Sameek Roychowdhury , Saeed Sadeghi , Rachna T. Shroff , Ai Li , Jose Soto , Francesca Avogadri , Carl L. Dambkowski , Milind M. Javle

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT03773302

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS4171)

DOI

10.1200/JCO.2022.40.16_suppl.TPS4171

Abstract #

TPS4171

Poster Bd #

151a

Abstract Disclosures

Similar Posters

First Author: Milind M. Javle

First Author: Tanios S. Bekaii-Saab

Poster

2020 Gastrointestinal Cancers Symposium

Phase II study of copanlisib in combination with gemcitabine and cisplatin in advanced cholangiocarcinoma.

Phase II study of copanlisib in combination with gemcitabine and cisplatin in advanced cholangiocarcinoma.

First Author: Elaine Tan

First Author: Do-Youn Oh